Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Adult Soft Tissue Sarcomas: An Overview

Treatment of Adult Soft Tissue Sarcomas: An Overview Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient’s wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Treatment of Adult Soft Tissue Sarcomas: An Overview

Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/treatment-of-adult-soft-tissue-sarcomas-an-overview-VXCNTRV0vB
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0011-x
Publisher site
See Article on Publisher Site

Abstract

Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient’s wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas.

Journal

Oncology and Therapy – Springer Journals

Published: Sep 7, 2015

References

  • Cancer statistics
    Jemal, A; Tiwari, RC; Murray, T
  • Cancer statistics
    Siegel, RL; Miller, KD; Jemal, A
  • Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons
    Lawrence, W; Donegan, WL; Ntarajan, N; Mettlin, C; Beart, R; Winchester, D
  • Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients
    Fong, Y; Coit, DG; Woodruff, JM; Brennan, MF
  • Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients
    Zagars, GK; Ballo, MT; Pisters, PW; Pollock, RE
  • Soft tissue sarcoma should be treated at a tumor center. A comparaison of quality of surgery in 375 patients
    Gustafson, P; Dreinhofer, KE; Rydholm, A
  • Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register
    Trovik, CS; Bauer, HC; Alvegrad, TA
  • Quality of surgery in soft tissue sarcoma: a single centre experience with the French Sarcoma Group (FSG) surgical system
    Stoeckle, E; Coindre, JM; Kantor, G
  • The treatment of soft tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy
    Rosenberg, SA; Tepper, J; Glastein, E
  • Prospective randomized evaluation of adjuvant radiotherapy in adults with soft tissue sarcomas of the extremities
    Rosenberg, SA; Tepper, J; Glatskin, E
  • Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long term functional results
    Keus, RB; Rutgers, EJ; Ho, GH; Gortzak, E; Albus-lutter, CE; Hart, AA
  • Up ToDate
    Delaney, TF; Harmon, DC; Gebhardt, MC
  • Role of sentinel lymph node biopsy in the staging of synovial, epitheloid, and clear cell sarcomas
    Maduekwe, UN; Hornicek, FJ; Springfield, DS
  • Sentinel node biopsy in soft tissue sarcoma subtypes with high propensity for regional lymphatic spread–results of a large prospective trial
    Andreou, D; Boltdt, H; Werner, M; Hamann, C; Pink, D; Tunn, PU
  • Long term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk
    Baldini, EH; Gildgerg, J; Jenner, C
  • Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas
    Pisters, PW; Pollock, RE; Lewis, VO
  • A prospective nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation
    Cahlon, O; Brennan, MF; Jia, X; Qin, LX; Singer, S; Atektiar, KM
  • Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity
    Yang, JC; Chang, AE; Baker, AR
  • Long-term results of prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma
    Pisters, PW; Harisson, LB; Leung, DH; Woodruff, JM; Casper, ES; Bernnan, MF
  • Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities
    Pisters, PW; Leung, DH; Woodruff, J; Shi, W; Brennan, MF
  • Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register
    Trovik, CS; Bauer, HC; Alvegård, TA
  • Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy
    Zagars, GK; Ballo, MT; Pisters, PW; Pollock, RE; Patel, SR; Benjamin, RS
  • Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities
    Khanfir, K; Alzieu, L; Terrier, P
  • Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group
    Coindre, JM; Terrier, P; Bui, NB
  • Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
    O’Sullivan, B; Davis, AM; Turcotte, R
  • Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma
    O’Sullivan, B; Griffin, AM; Dickie, CI
  • Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas
    Lindberg, RD; Martin, RG; Romsdahl, MM; Barkley, HT
  • Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
  • A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
    Pervaiz, N; Colterjohn, N; Farrokhyar, F; Tozer, R; Figueredo, A; Ghert, M
  • Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials
    Cesne, A; Ouali, M; Leahy, MG
  • Differential sensitivity of liposarcoma subtypes to chemotherapy
    Jones, RL; Fisher, C; Al-Muderis, O; Judson, IR
  • Synovial sarcoma. Uniform response of metastases to high dose ifosfamide
    Rosen, G; Forscher, C; Lowenbraun, S
  • Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at single institution
    Ferrari, A; Gronchi, A; Casanova, M
  • The impact of chemotherapy on the survival of patients with high grade primary extremity liposarcoma
    Eilber, FC; Eilber, FR; Eckardt, J
  • Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study
    Angele, MK; Albertsmeier, M; Prix, NJ
  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high risk soft tissue sarcoma: a randomised phase 3 multicentre study
    Issel, RD; Lindner, LH; Verweij, J
  • High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma result in a >90% response and limb preservation
    Gutman, M; Inbar, M; Lev-Shulsh, D
  • Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectabe extremity soft tissue sarcomas: a multicenter trial
    Eggermont, AM; Schraffordt Koops, H; Liénard, D
  • Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresctable soft tissue sarcoma of the extremities
    Noorda, EM; Vrouenraets, BC; Nieweg, OE; Coevorden, F; Slooten, GW; Kroon, BB
  • Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma
    Grunhagen, DJ; Wilt, JH; Graveland, WJ; Verhoef, C; Geel, AN; Eggermont, AM
  • Neoadjuvant combined with regional hypertermia for locally advanced primary or recurrent high risk adult soft tissue sarcomas of adults: long term results of phase II study
    Issels, RD; Abdel-Rahman, S; Wendtner, C
  • Phase I trial of preoperative doxorubicin based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas
    Pister, PW; Patel, SR; Prieto, VG
  • Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa
    Toma, S; Canavese, G; Grimaldi, A
  • Concurrent ifisfamide-based chemotherapy and irradiation. Analysis of treatment related toxicity in 43 patients with sarcoma
    Cormier, JN; Patel, SR; Herzog, CE
  • Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high risk, high grade, soft tissue sarcomas of the extremities and body wall
    Kraybill, WG; Harris, J; Spiro, IJ
  • A randomized phase II study on neo-adjuvant chemotherapy for high-risk adult soft tissue sarcoma
    Gortzak, E; Azzarelli, A; Buesa, J
  • An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue sarcomas
    Antman, K; Crowley, J; Blacerzak, SP
  • Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy
    Elias, A; Ryan, L; Sulkes, A; Collins, J; Aisner, J; Antman, KH
  • Treatment and local control of primary extremity soft tissue sarcomas
    Driscoll, DL
  • Prognostic factors for diseases-specific survival after first relapse of soft tissue sarcomas: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy
    Zagars, GK; Ballo, MT; Piester, PW; Pollock, RE; Patel, SR; Benjamin, RS
  • Outcome and prognostic factors in soft tissue sacoma in the adult
    Levay, J; O’Sullivan, B; Catton, C
  • Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma
    Indelicato, DJ; Meadows, K; Gibbs, CP; Morris, CG; Scarborough, MT; Zlotecki, RA
  • Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field
    Pearlstone, DB; Janjan, NA; Feig, BW
  • Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs
    Lans, TE; Grünhagen, DJ; Wilt, JH; Geel, AN; Eggermont, AM
  • Trends in survival for patients with metastatic soft-tissue sarcoma
    Italiano, A; Mathoulin-Pelissier, S; Cesne, A
  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatisoft-tissue sarcoma: a randomised controlled phase 3 trial
    Judson, I; Verweij, J; Gelderblom, H
  • Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
    Blay, JY; Glabbeke, M; Verweij, J
  • Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival
    Blackmon, SH; Shah, N; Roth, JA
  • Pulmonary metatases from soft tissue sarcoma: analysis of patterns of disease and postmetastases survival
    Billingsley, KG; Burt, ME; Jara, E
  • Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline
    Bramwell, VH; Anderson, D; Charette, ML
  • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group
    Judson, I; Radford, JA; Harris, M
  • The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
    Tascilar, M; Loos, WJ; Seynaeve, C; Verweij, J; Sleijfer, S
  • Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
    Oosterom, AT; Mouridsen, HT; Nielsen, OS
  • High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose response and schedule dependence
    Patel, S; Vadhan-Raj, S; Papadopolous, N
  • Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research
    Sleijfer, S; Ouali, M; Glabbeke, M
  • Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
    Lorigan, PL; Verweij, J; Papai, Z
  • High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas
    Cesne, A; Antoine, E; Spielmann, M
  • Role of DTIC (NSC-45388) in the chemotherapy of sarcomas
    Gottlieb, JA; Benjamin, RS; Baker, LH
  • The “old drug” dacarbazine as second/third line chemotherapy in advanced soft tissue sarcomas
    Zucali, PA; Bertuzzi, A; Parra, HJ; Campagnoli, E; Qualiuolo, V; Santoro, A
  • A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas
    Garcia del Muro, X; Lopez-Pousa, A; Martin, J
  • Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study
    Penel, N; Bui, BN; Bay, JO
  • Randomized multicenter and stratified phase II of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer French Sarcoma Group Study (TAXOGEM)
    Pautier, P; Floquet, A; Penel, N
  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002
    Maki, RG; Wathen, JK; Patel, SR
  • A phase II study of docetaxel in chemotherapy-naïve patients with recurrent or metastatic adult soft tissue sarcoma
    Bramwell, V; Blackstein, M; Belanger, K
  • Phase II trial of carboplatin in soft tissue sarcoma
    Goldstein, D; Cheuvart, B; Trump, DL
  • Paclitaxel in patients with advanced, angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group
    Schlemmer, M; Reichardt, P; Verweij, J
  • An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    Hartmann, JT; Oechsle, K; Huober, J
  • Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma
    Burton, G; Rankin, C; Zalupski, MM
  • Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network
    Stacchiotti, S; Palassini, E; Sanfilippo, R
  • Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
    Schoffski, P
  • A retrospective pooled analysis of trabectedin safety in 1132 patients with solid tumors treated in phase II clinical trials
    Cesne, A
  • Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
    Demetri, GD; Chawla, SP; Mehren, M
  • Randomized comparison of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue sarcomas
    Antman, K; Crowley, J; Balcerzak, SP
  • Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas
    Borden, EC; Amato, DA; Rosenbaum, C
  • Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study
    García-Del-Muro, X; López-Pousa, A; Maurel, J
  • Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organization for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
    Kasper, B; Sleijfer, S; Litière, S
  • Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
    Kasper, B; Sleijfer, S; Litière, S
  • Cediranib for metastatic alveolar soft part sarcoma
    Kummar, S; Allen, D; Monks, A
  • Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response
    Stacchiotti, S; Negri, T; Palassini, E
  • Response to sunitinib malate in advanced alveolar soft part sarcoma
    Stacchiotti, S; Tamborini, E; Marrari, A
  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    Butrynski, JE; D’Adamo, DR; Hornick, JL
  • Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
    Wagner, AJ; Malinowska-Kolodziej, I; Morgan, JA